Hypercortisolism Caused by Ritonavir Associated Inhibition of CYP 3A4 Under Inhalative Glucocorticoid Therapy. 2 Case Reports and a Review of the Literature

 

 Buy Article Permissions and Reprints

Abstract

Recent in vitro and in vivo studies have shown a potent inhibition of cytochrome P450 CYP3A4 through human immune deficiency virus (HIV) protease inhibitors (PIs). The PI ritonavir is described as the most potent compound within these CYP3A4 inhibitors. We present 2 cases who developed the sequelae of glucocorticoid excess following ritonavir therapy and inhalative glucocorticoid treatment: A 60-year-old HIV positive man developed the typical symptoms of Cushing’s syndrome and a 52-year-old HIV positive man developed severe osteoporosis.

• References

• 1 Aaron SD, Bishop G, Anthony J et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146 (08) 545-555
  CrossrefPubMedGoogle Scholar
• 2 Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998; 157 (3 Pt 2) 51-53
  PubMedGoogle Scholar
• 3 Calverley PM, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789
  CrossrefPubMedGoogle Scholar
• 4 Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 2000; 30 (Suppl. 02) S135-S142
  CrossrefPubMedGoogle Scholar
• 5 Chen F, Kearney T, Robinson S et al. Cushing’s syndrome and severe adrenal suppression in patients treated with ritonavir and inhaled nasal fluticasone. Sex Transm Infect 1999; 75 (04) 274
  PubMedGoogle Scholar
• 6 Dassinger M, Grohmann I, Jung B et al. Kombinationen mit beta-2Adrenorezeptor-Agonisten. In: Rote Liste, Frankfurt: Rote Liste Service GmbH 2011; 892-895
  PubMedGoogle Scholar
• 7 Drummond MB, Dasenbrook EC, Pitz MW et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300: 2407-2416
  CrossrefPubMedGoogle Scholar
• 8 Ernest 2nd CS, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 2005; 312: 583-591
  PubMedGoogle Scholar
• 9 Hubbard R, Tattersfield A, Smith C et al. Use of inhaled corticosteroids and the risk of fracture. Chest 2006; 130: 1082-1088
  CrossrefPubMedGoogle Scholar
• 10 Hubbard RB, Smith CJ, Smeeth L et al. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med 2002; 166 (12 Pt 1) 1563-1566
  CrossrefPubMedGoogle Scholar
• 11 Johnson SR, Marion AA, Vrchoticky T et al. Cushing’s syndrome with secondary adrenal insufficiency from concomitant therapy with ritonavir and fluticasone. J Pediatr 2006; 148: 386-388
  CrossrefPubMedGoogle Scholar
• 12 Kannisto S, Laatikainen A, Taivainen A et al. Serum dehydroepiandrosterone sulfate concentration as an indicator of adrenocortical suppression during inhaled steroid therapy in adult asthmatic patients. Eur J Endocrinol 2004; 150: 687-690
  CrossrefPubMedGoogle Scholar
• 13 Kroiss M, Quinkler M, Lutz WK et al. Drug interaction with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol 2011; 75: 585-591
  CrossrefPubMedGoogle Scholar
• 14 Kumar GN, Jayanti VK, Johnson MK et al. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans. Pharm Res 2004; 21: 1622-1630
  CrossrefPubMedGoogle Scholar
• 15 Lamba JK, Lin YS, Schuetz EG et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54: 1271-1294
  CrossrefPubMedGoogle Scholar
• 16 Liu YT, Hao HP, Liu CX et al. Drugs as CYP3A probes, inducers and inhibitors. Drug Metab Rev 2007; 39: 699-721
  CrossrefPubMedGoogle Scholar
• 17 Meena LP, Rai M, Singh SK et al. Endocrine changes in male HIV patients. J Assoc Physicians India 2011; 59: 365-371
  PubMedGoogle Scholar
• 18 Resmini E, Farkas C, Murillo B et al. Body composition after endogenous (Cushing’s syndrome) and exogenous (rheumatoid arthritis) exposure to glucocorticoids. Horm Metab Res 2010; 42: 613-618
  Article in Thieme ConnectPubMedGoogle Scholar
• 19 Todd GR, Acerini CL, Ross-Russell R et al. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002; 87: 457-461
  CrossrefPubMedGoogle Scholar
• 20 Von Moltke LL, Greenblatt DJ, Grassi JM et al. Protease inhibitors as inhibitors of human cytochromees P450: high risk associated with ritonavir. J Clin Pharmacol 1998; 38: 106-111
  PubMedGoogle Scholar
• 21 Valin N, De Castro N, Garrait V et al. Iatrogenic Cushing’s syndrome in HIV-infected patients receiving ritonavir and inhaled fluticasone: description of 4 new cases and review of the literature. J Int Assoc Physicians AIDS Care (CHIC) 2009; 8: 113-121
  CrossrefPubMedGoogle Scholar
• 22 van Erp NP, Guchelaar HJ, Ploeger BA et al. Mitotane has a strong and a durable inducing effect on CYP3A4 activity. Eur J Endocrinol 2011; 164: 621-626
  CrossrefPubMedGoogle Scholar
• 23 Wainberg MA, Zaharatos GJ, Brenner BG. development of antiretroviral drug resistance. N Engl J Med 2011; 365: 637-646
  CrossrefPubMedGoogle Scholar